Columbus, OH 的 鐮狀細胞病 臨床試驗
9 項針對 鐮狀細胞病 的研究正在 Columbus（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
招募中3 期
- Ohio State Univ Wexner Med Ctr, Columbus
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
招募中觀察性研究
- Ohio State University Medical Center, Columbus
- Nationwide Children's Hospital Columbus, Columbus
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
招募中2 期
- The Ohio State University, Columbus
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
招募中2 期
- Ohio State University, Columbus
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
招募中1/2 期
- Nationwide Children's Hospital, Columbus
Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
招募中觀察性研究
- Nationwide Children's Hospital (NT-DMT), Columbus
Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
招募中
- The Ohio State University Medical Center, Columbus
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
招募中2 期
- Nationwide Children's Hospital, Columbus
HPC Offered for PRESERVE Expansion
招募中觀察性研究
- The Ohio State University Medical Center, Columbus
其他城市的 鐮狀細胞病 試驗
- Atlanta, GA22 項研究
- Washington, DC20 項研究
- Memphis, TN18 項研究
- Chicago, IL18 項研究
- Philadelphia, PA15 項研究
- Birmingham, AL14 項研究
- New York City, NY13 項研究
- St. Louis, MO12 項研究
- Durham, NC10 項研究
- Cincinnati, OH10 項研究
- Houston, TX10 項研究
- Boston, MA10 項研究
Columbus 的其他研究
- 非小細胞肺癌56 項研究
- 乳癌39 項研究
- 卵巢癌39 項研究
- 癌症（所有類型）38 項研究
- 肺癌37 項研究
- 急性髓系白血病35 項研究
- 慢性淋巴性白血病28 項研究
- 轉移性癌症27 項研究
- 子宮內膜癌25 項研究
- 大腸直腸癌24 項研究
- 前列腺癌24 項研究
- 多發性骨髓瘤24 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。